Efgartigimod for generalized myasthenia gravis with or without anti-acetylcholine receptor antibodies: a worldwide and Japanese perspective
Sign Up to like & getrecommendations! Published in 2022 at "Expert Review of Clinical Immunology"
DOI: 10.1080/1744666x.2022.2136167
Abstract: ABSTRACT Introduction The management of myasthenia gravis (MG) has been improved due to immunotherapy advances, but 20% of individuals with MG are refractory to the conventional therapy, and the need for novel biological drugs remains.… read more here.
Keywords: anti acetylcholine; receptor antibodies; without anti; acetylcholine receptor ... See more keywords